Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 18,805 | 52,713 | 28,238 | 46,329 | 21,988 |
| Marketable Securities | 148,669 | 142,213 | 195,513 | 206,669 | 259,895 |
| Receivables | 2,144 | 5,116 | 5,035 | 11,738 | 10,081 |
| TOTAL | $174,767 | $203,285 | $233,896 | $315,243 | $350,208 |
| Non-Current Assets | |||||
| PPE Net | 5,633 | 6,304 | 6,983 | 7,728 | 15,588 |
| Investments And Advances | 2,995 | 2,781 | 2,624 | 2,007 | 2,130 |
| Intangibles | 0 | 10,513 | 12,561 | 12,643 | 12,763 |
| Other Non-Current Assets | 9,703 | 10,156 | 10,518 | 10,912 | 11,279 |
| TOTAL | $18,330 | $29,754 | $32,686 | $33,291 | $41,760 |
| Total Assets | $193,097 | $233,038 | $266,583 | $348,533 | $391,968 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 16,266 | 22,952 | 26,170 | 80,907 | 75,782 |
| Accrued Expenses | 5,011 | 6,172 | 5,796 | 10,594 | 13,486 |
| TOTAL | $43,711 | $51,932 | $55,151 | $96,868 | $94,915 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 3,828 | 3,749 | 4,211 | 2,563 | 2,827 |
| Other Non-Current Liabilities | 11,195 | 11,702 | 12,186 | 29,271 | 30,324 |
| TOTAL | $11,227 | $11,734 | $12,218 | $29,303 | $30,356 |
| Total Liabilities | $54,938 | $63,666 | $67,369 | $126,171 | $125,271 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 22,740 | 22,331 | 21,886 | 21,669 | 20,782 |
| Common Shares | 270 | 268 | 263 | 21 | 250 |
| Retained earnings | -1,597,962 | -1,564,032 | -1,528,497 | -1,487,848 | -1,433,385 |
| Other shareholders' equity | -751 | -691 | -583 | -698 | -885 |
| TOTAL | $138,160 | $169,372 | $199,214 | $222,363 | $266,697 |
| Total Liabilities And Equity | $193,097 | $233,038 | $266,583 | $348,533 | $391,968 |